Enzo Biochem (ENZ) Reports Q1 Loss of $0.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Enzo Biochem Reports Fiscal First Quarter Results
December 10, 2019 4:15 PM ESTCompany Announces Plan to Unlock Value for Therapeutics Subsidiary
Announces Three Lab-to-Lab Relationships
Announces Appointment of New Chief Financial Officer
Enzo Continues to Take Steps in Creating New Model for Modern Day Diagnostics Company
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYSE: ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported... More
